Thom Tillis argues against government intervention in free markets

4 articles · Updated · Fortune · Apr 30

In a Fortune commentary, the Republican senator cites housing, drug pricing and university patent licensing as areas where federal action could cut construction, research investment and commercialisation.
He says restricting institutional buyers of single-family rentals would worsen shortages, while importing foreign-style drug price controls could delay hundreds of medicines by reducing incentives for private investment.
Tillis also warns against government equity stakes and greater control over companies, arguing the US should lower costs through zoning reform, supply-chain fixes and lighter regulation instead.

As America brings drug manufacturing home, will patients see lower prices or fewer life-saving cures?

With government buying stakes in private firms, who really benefits: taxpayers or politically connected companies?

Will new housing policies build more homes for families or just build higher walls for investors?